Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma

Lung adenocarcinoma (LUAD) is the most common and lethal cancer worldwide. Radiotherapy (RT) is widely used at all stages of LUAD, and the development of immunotherapy substantially enhances the survival of LUAD patients. Although the emerging treatments for LUAD have improved prognosis, only a smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Linzhi, Shi, Hongjie, Luo, Yuan, Sun, Wenjie, Li, Shuying, Zhang, Nannan, Jiang, Xueping, Gong, Yan, Xie, Conghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774727/
https://www.ncbi.nlm.nih.gov/pubmed/33098370
http://dx.doi.org/10.1002/cam4.3561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774727/
https://www.ncbi.nlm.nih.gov/pubmed/33098370
http://dx.doi.org/10.1002/cam4.3561

Ejemplares similares